VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | ZUMA-14 updates and the promise of dual antigen targeting approaches

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some updates from the ZUMA-14 trial (NCT04002401) investigating the safety and efficacy of rituximab in combination with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). Dr Patel comments on the overall response rate (ORR) and progression-free survival (PFS) observed, and further highlights the promise of dual antigen targeting treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter